Bavarian Nordic AS (BVNKF) reports robust financial performance with significant growth in travel health and strategic expansions in vaccine markets.

How Bavarian Nordic stock has been performing Bavarian Nordic (CPSE:BAVA) has seen mixed share performance recently, with the stock up 2.6% over the past week but down about 1.4% over the past month. Over the past 3 months, the share price is roughly flat, while the year to date return stands at about 0.9%. Looking further back, the stock has gained around 16.8% over the past year but is lower over the past 3 and 5 years. See our latest analysis for Bavarian Nordic. At a share price of...

If you are wondering whether Bavarian Nordic at DKK195.70 is offering genuine value or just riding sentiment, the key is to look closely at what the current price implies about the business. The stock has returned 2.5% over the past 7 days, 4.3% over 30 days, 1.5% year to date and 36.7% over the last 12 months, which raises questions about how much of this performance is already reflected in the valuation. Recent coverage around Bavarian Nordic has focused on its position as a Denmark-listed...

What recent performance tells you about Bavarian Nordic Bavarian Nordic (CPSE:BAVA) has drawn fresh attention after its recent share price moves, with the stock showing positive returns over the past week, month, past 3 months and year. That price action is prompting some investors to revisit the company’s fundamentals, including its reported DKK 6,243.956 thousand in revenue and DKK 1,375.378 thousand in net income, along with its value score of 6. See our latest analysis for Bavarian...

If you are wondering whether Bavarian Nordic is priced attractively right now, this article will walk you through what the current share price might be implying about its underlying value. The stock closed at DKK 181.55 recently, with a 7 day return of 0.6% decline, a 30 day return of 5.4% decline and a year to date return of 5.8% decline. The 1 year return sits at 8.5% and the 3 year return at 1.9%, compared to a 5 year return of 36.9% decline. Recent news around Bavarian Nordic has focused...

Bavarian Nordic AS (BVNKF) reports robust revenue growth and strategic expansions, despite challenges in vaccine shelf life and increased expenses.

The new arrangement builds upon the existing mpox vaccine licence and manufacturing partnership between the two companies.

Event driven snapshot Bavarian Nordic (CPSE:BAVA) recently drew investor attention after a daily share price decline of 2.6%, extending a 7% drop over the past week and adding context to its recent trading pattern. See our latest analysis for Bavarian Nordic. That 2.6% daily share price decline and 7.5% 7 day share price pullback sit against a softer 30 day share price return of 7.1% and a year to date share price decline of 5.3%, while the 1 year total shareholder return of 8.8% points to...

Leaders at Bavarian Nordic, Sarepta and Alkermes recently announced plans to step down.